Renal failure in myelomatosis.

Abstract

Renal failure is a common presenting feature in myelomatosis. This review offers a practical means for classifying renal failure in this disease. Three groups are identified: (1) those patients whose renal failure improves or is stable when they are maintained on a high fluid intake; (2) the minority of patients whose renal failure progresses despite high fluid intake; and (3) those patients who are fluid-intolerant due to oliguric renal failure or congestive cardiac failure. The difference between groups 1 and 2 is not simply due to differences in response to chemotherapy, for many group-1 patients achieve improvement in renal function without or before loss of light chain proteinuria. It is concluded that all patients with myelomatosis with excess monoclonal free light chain proteinuria are at risk from developing renal failure of the type associated with group 1. The chances of them doing so are diminished if they maintain a high fluid intake. Group 2 encompasses a range of conditions not all of which are clearly defined. There is generally a poor correlation between the physical characteristics of light chains and the presence of group-2 renal failure.

• Authors: I C MacLennan, E H Cooper, C E Chapman, K A Kelly, R A Crockson
• Journal: European journal of haematology. Supplementum (Eur J Haematol Suppl) Vol. 51 Pg. 60-5 ( 1989) ISSN: 0902-4506 [Print] England
• PMID: 2516808 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Immunoglobulin Light Chains
• Myeloma Proteins

Topics

• Acute Kidney Injury (etiology, mortality, therapy)
• England (epidemiology)
• Fluid Therapy
• Humans
• Immunoglobulin Light Chains (urine)
• Kidney Failure, Chronic (etiology, mortality)
• Multiple Myeloma (complications, mortality, urine)
• Myeloma Proteins (urine)
• Survival Rate